This is an prospective study to evaluate the safety and efficacy of naxitamab monotherapy or combined with chemotherapy or combined with chemotherapy and checkpoint inhibitor in the treatment of pediatric high-risk and refractory/relapsed neuroblastoma in Sun Yat-sen University Cancer Center.
None
Significant organ toxicity
Known or suspected allergy or hypersensitivity to anti-GD2 antibodies or to GM-CSF or its s components.
Patient is pregnant, planning to become pregnant (while being treated with naxitamab) or is currently breastfeeding
Patient will undergo treatment with another investigational drug, whilst being treated with naxitamab or has received another investigational drug within the 4 weeks prior to commencing treatment with naxitamab
Sun Yat-Sen University Cancer Center
Lead sponsor
Hainan General Hospital
Collaborator